All In Biotech

Drug Trial Radar · NCT04833894

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Open-label Uncontrolled Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Activity of Efgartigimod in Children From 2 to Less Than 18 Years of Age With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

15

Actual

Start

Oct 26, 2021

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Apr 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • Efgartigimod IVBiological

    Intravenous infusion of Efgartigimod

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Clearance (CL)Time frame: up to 26 weeks
  2. Efgartigimod concentrations as input for compartmental, model-driven analysis to determine (age and size dependency of) Volume of Distribution (Vd)Time frame: up to 26 weeks
  3. Total Immunoglobulin G (IgG) levels as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysisTime frame: up to 26 weeks
  4. Anti-acetylcholine receptors antibodies (AChR-Ab) as input for pharmacokinetics (PK) and pharmacodynamics (PD) modeling analysisTime frame: up to 26 weeks

Locations

25 sites in 12 countries. Site status is shown where the registry gives one.

  • Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital

    Chicago, Illinois

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • University of Virginia (UVA) Health - Developmental Pediatrics Clinic

    Charlottesville, Virginia

  • Medizinische Universitat Wien

    Vienna, Austria

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium

  • Alberta Childrens Hospital

    Calgary, Canada

  • British Columbia Children's Hospital

    Vancouver, Canada

  • AP-HM - Hopital de la Timone

    Marseille, France

  • Assistance Publique Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades

    Paris, France

  • Vian - M. Iashvili Children's Central Hospital

    Tbilisi, Georgia

  • Tbilisi State Medical University - Givi Zhvania Pediatric Academic Clinic

    Tbilisi, Georgia

  • Charite Universitaetsmedizin Berlin - Campus Virchow-Klinikum - Sozialpadiatrisches Zentrum

    Berlin, Germany

  • Universitätsklinikum Essen

    Essen, Germany

  • Azienda Ospedaliera Universitaria Policlinico Consorziale Di Bari

    Bari, Italy

  • Azienda Ospedaliero Universitaria A. Meyer

    Florence, Italy

  • Ospedale Giannina Gaslini

    Genova, Italy

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

  • Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM

    Warsaw, Poland

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Woj. Pomorskie, Poland

  • Wielospecjalistyczna Poradnia Lekarska Synapsis

    Katowice, Woj. Slaskie, Poland

  • Hospital Sant Joan de Deu

    Esplugues de Llobregat, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

  • Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital

    London, United Kingdom

  • Manchester University NHS Foundation Trust - Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital Children's Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.